08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV E2 In vitro studies solved the structure of the HCV E2 protein, which could aid HCV vaccine and drug design. X-ray crystal...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

MassBiologics preclinical data

In chimpanzees, a single dose of 250 mg/kg HCV1 given 30 minutes prior to exposure to HCV genotype 1a provided complete protection from viral infection, while single dose of 50 mg/kg HCV1 provided no protection....
07:00 , Apr 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV envelope glycoproteins In vitro and mouse studies have identified mAbs binding to HCV envelope glycoproteins that could help treat or prevent infection....
07:00 , Apr 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV E2 In vitro studies suggest that a vaccine that avoids eliciting antibodies against a particular viral epitope may...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Clinical News

XTL-6865: Phase I data

In a dose-escalation, placebo-controlled Phase I trial in 32 HCV patients, XTL-6865 was safe. The trial involved 8 cohorts of 4 patients each, with 3 receiving XTL-6865 and 1 getting placebo. The first 7 cohorts...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Dov Pharmaceuticals Inc., XTL deal

DOV received $7.5 million up front, $5 million of which went to Wyeth (WYE, Madison, N.J.) as a milestone under the partners' 2004 amendments to a 1997 deal (see BioCentury, March 1, 2004, & July...
08:00 , Nov 6, 2006 |  BioCentury  |  Regulation

HCV antivirals

HCV antivirals HCV antivirals Selected HCV antiviral agents in clinical development. (A) Plans to start a Phase IIb program to test Viramidine at higher doses after mixed results were seen in two Phase III trials;...
02:46 , Mar 21, 2006 |  BC Extra  |  Financial News

XTL raises $28 million

XTL (LSE:XTL; XTLB) raised $28 million through a U.S. private placement of 4.7 million ADRs at $6, which is a 23% discount to Friday's close of $7.75. JPMorgan; Brean Murray; Carret; Oppenheimer; and Punk were...
08:00 , Dec 19, 2005 |  BC Week In Review  |  Company News

XTL infectious news

XTL updated its restructuring plans, and now expects to reduce headcount by an additional 13 employees, or about 25%. The reductions are primarily in early-stage research in Rehovot. In March, XTL said it would reduce...
01:08 , Dec 17, 2005 |  BC Extra  |  Company News

XTL updates restructuring plans

XTL (LSE:XTL; XTLB) updated its restructuring plans, and now expects to reduce headcount by an additional 13 employees, or about 25%. The reductions are primarily in early-stage research in Rehovot. In March, XTL said it...